Ran Linhao, Jiang Li, Liu Ying, Pang Hua
Department of Nuclear Medicine, Banan People's Hospital, Chongqing Medical University, Chongqing 401320, P.R. China.
Department of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China.
Oncol Lett. 2025 Apr 9;29(6):285. doi: 10.3892/ol.2025.15031. eCollection 2025 Jun.
Patients with advanced non-small cell lung cancer (NSCLC) have seen improvements in care; however, outcomes remain poor for certain individuals despite treatment with radiation, chemotherapy, targeted therapies and immunotherapy. The present study aimed to assess the safety and efficacy of combining 8Spheres microsphere embolization with iodine-125 seed implantation for treating advanced refractory NSCLC. The retrospective analysis included 45 patients with advanced refractory NSCLC. Using the surv_cutpoint function in R, the optimal maximum tumor diameter threshold was determined as 53 mm, dividing patients into two groups: ≤53 mm and >53 mm. The study evaluated the association between treatment regimen, tumor diameter, and progression-free survival (PFS) and overall survival (OS). The findings demonstrated that the experimental group achieved a significantly longer median PFS (12 vs. 10 months; P=0.006) and OS (19 vs. 12 months; P=0.032) compared with the control group. Both the treatment approach and tumor size were identified as independent factors influencing survival. The risk of death was 2.291-fold higher for patients on the control regimen than for those in the experimental group. Similarly, patients with a tumor diameter of >53 mm had a 2.723-fold higher risk of death than those with a tumor diameter of ≤53 mm. Adverse events were mild and resolved in both groups. In summary, the combination of 8Spheres microsphere embolization and iodine-125 seed implantation demonstrate promising clinical outcomes and it may be a viable treatment for advanced refractory NSCLC. Additionally, maximum tumor diameter was strongly associated with patient survival and therefore it may serve as a valuable prognostic indicator to guide treatment decisions.
晚期非小细胞肺癌（NSCLC）患者的治疗已有所改善；然而，尽管接受了放疗、化疗、靶向治疗和免疫治疗，但某些患者的预后仍然很差。本研究旨在评估8Spheres微球栓塞联合碘-125粒子植入治疗晚期难治性NSCLC的安全性和有效性。回顾性分析纳入了45例晚期难治性NSCLC患者。使用R语言中的surv_cutpoint函数，将最佳最大肿瘤直径阈值确定为53mm，将患者分为两组：≤53mm和>53mm。该研究评估了治疗方案、肿瘤直径与无进展生存期（PFS）和总生存期（OS）之间的关联。结果表明，与对照组相比，实验组的中位PFS（12个月对10个月；P=0.006）和OS（19个月对12个月；P=0.032）显著更长。治疗方法和肿瘤大小均被确定为影响生存的独立因素。对照组患者的死亡风险比实验组高2.291倍。同样，肿瘤直径>53mm的患者的死亡风险比肿瘤直径≤53mm的患者高2.723倍。两组的不良事件均较轻且已缓解。总之，8Spheres微球栓塞联合碘-125粒子植入显示出有前景的临床结果，可能是晚期难治性NSCLC的一种可行治疗方法。此外，最大肿瘤直径与患者生存密切相关，因此可作为指导治疗决策的有价值的预后指标。
